Category: News & Events

Combination of Neutrophil Count and Gensini Score as a Prognostic Marker in Patients with Acute Coronary Syndrome and Uncontrolled Type 2 Diabetes Mellitus Undergoing Percutaneous Coronary Intervention

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Several biomarkers have been studied as prognostic indicators among people with diabetes and coronary artery disease (CAD). The purpose of this study was to determine the prognostic value of neutrophil counts and the Gensini score in patients with type 2 diabetes (T2DM) and Acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI).

A total of 694 people with ACS and T2DM who simultaneously had elevated HBA1c received PCI. Spearman rank correlation estimates were used for correlation evaluation. Multivariate Cox regression and Kaplan-Meier analysis were used to identify characteristics associated with major adverse cardiovascular and cerebrovascular events (MACCEs) and patient survival. The effects of single- and multi-factor indices on MACCEs were evaluated through receiver operating characteristic curve analysis.

The Gensini score and neutrophil count significantly differed between the MACCE and non-MACCE groups among patients receiving PCI who had concomitant ACS and T2DM with elevated HBA1c (P<0.001). The Gensini score and neutrophil count were strongly associated with MACCEs (log-rank, P<0.001). The Gensini score and neutrophil count, alone or in combination, were predictors of MACCEs, according to multivariate Cox regression analysis (adjusted hazard ratio [HR], 1.005; 95% confidence interval [CI], 1.002–1.008; P=0.002; adjusted HR, 1.512; 95% CI, 1.005–2.274; P=0.047, respectively). The Gensini score was strongly associated with neutrophil count (variance inflation factor ≥ 5). Area under the curve analysis revealed that the combination of multivariate factors predicted the occurrence of MACCEs better than any single variable.

In patients with T2DM and ACS with elevated HBA1c who underwent PCI, both the Gensini score and neutrophil count were independent predictors of outcomes. The combination of both predictors has a higher predictability.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0051

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Yanyan Xu, Zhen Qin and Jiamin Gao et al. Combination of Neutrophil Count and Gensini Score as a Prognostic Marker in Patients with ACS and Uncontrolled T2DM Undergoing PCI. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0051

Loading

It’s Time to Consider Ablation as First-Line Therapy for Atrial Fibrillation

Announcing a new article publication for Cardiovascular Innovations and Applications journal.   Atrial fibrillation is the most common arrhythmia worldwide, affecting millions of the general population. It is a leading cause of stroke and is associated with many other long-term adverse cardiovascular issues. Long-term management of atrial fibrillation can involve simply controlling the ventricular rate with AV nodal blocking agents (rate control strategy) versus restoring and maintaining sinus rhythm (rhythm control strategy). For many years, pharmacologic rate control or rhythm control were both considered acceptable first-line therapeutic strategies. More recently, however, catheter ablation has emerged as a viable and potentially more effective treatment option than drug therapy, especially in patients with heart failure. Given the increasing efficacy and safety of ablation, practice is evolving toward ablation being considered first-line therapy for more patients. Indeed, both the 2014 AHA/ACC/HRS guidelines and the 2020 ESC guidelines for management of atrial fibrillation state that ablation can be considered as a first-line approach in patients with either symptomatic paroxysmal or persistent atrial fibrillation. In this article the authors discuss evidence supporting catheter ablation as first-line therapy for atrial fibrillation.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0052

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Steven Ross and William Miles. It’s Time to Consider Ablation as First-Line Therapy for Atrial Fibrillation. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0052

Loading

Deep Learning-based Handheld Device-Enabled Symptom-driven Recording: A Pragmatic Approach for the Detection of Post-ablation Atrial Fibrillation Recurrence

Announcing a new article publication for Cardiovascular Innovations and Applications journal.  Symptom-driven electrocardiogram (ECG) recording plays a significant role in the detection of post-ablation atrial fibrillation recurrence (AFR). However, making timely medical contact whenever symptoms occur may not be practical. The authors of this article deployed a deep learning (DL)-based handheld device to facilitate symptom-driven monitoring.

A cohort of patients with paroxysmal atrial fibrillation (AF) was trained to use a DL-based handheld device to record ECG signals whenever symptoms presented after the ablation. Additionally, 24-hour Holter monitoring and 12-lead ECG were scheduled at 3, 6, 9, and 12 months post-ablation. The detection of AFR by the different modalities was explored.

A total of 22 of 67 patients experienced AFR. The handheld device and 24-hour Holter monitor detected 19 and 8 AFR events, respectively, five of which were identified by both modalities. A larger portion of ECG tracings was recorded for patients with than without AFR [362(330) vs. 132(133), P=0.01)], and substantial numbers of AFR events were recorded from 18:00 to 24:00. Compared to Holter, more AFR events were detected by the handheld device in earlier stages (HR=1.6, 95% CI 1.2–2.2, P<0.01).

The DL-based handheld device-enabled symptom-driven recording, compared with the conventional monitoring strategy, improved AFR detection and enabled more timely identification of symptomatic episodes.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0048

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Laite Chen and Chenyang Jiang. Deep Learning-based Handheld Device-Enabled Symptom-driven Recording: A Pragmatic Approach for the Detection of Post-ablation Atrial Fibrillation Recurrence. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0048

Loading

Research Hotspots and Trends in Home-Based Cardiac Rehabilitation: A Bibliometric Visualization Analysis

Announcing a new article publication for Cardiovascular Innovations and Applications journal. This research was aimed at determining research hotspots and major topics in the field of international home-based cardiac rehabilitation (HBCR) over the past 20 years and exploring future trends in HBCR. A total of 757 research articles from 2002 to 2022, with themes of home-based cardiac rehabilitation, were included in the core collection database of Web of Science. CiteSpace software was used for literature metrology and visualization analysis.

The total number of research articles on HBCR is increasing.

Research hotspots in HBCR include the effectiveness of rehabilitation after coronary heart disease or heart failure; quality of life; mental health; and home rehabilitation after COVID-19.

Research trends in HBCR include wearable intelligent technology; telerehabilitation; lifestyle interventions; and home-based rehabilitation prescriptions for exercise, nutrition, psychology and continuous management.

The effects of HBCR have been continuously verified. Research has focused primarily on secondary prevention and rehabilitation after coronary heart disease and heart failure. More attention must be paid to improving patients’ quality of life by HBCR. Telerehabilitation based on wearable intelligent technology, home-based lifestyle interventions and continuous management are future trends of HBCR development.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0045

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Li Jianchao, Zhao Yu and Tao Chunjing et al. Research Hotspots and Trends in Home-Based Cardiac Rehabilitation: A Bibliometric Visualization Analysis. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0045

Loading

Advances in Left Bundle Branch Pacing: Definition, Evaluation, and Applications

Announcing a new article publication for Cardiovascular Innovations and Applications journal.     Left bundle branch pacing (LBBP) emerged as a new physiological pacing strategy during the past several years. Recent observational studies have demonstrated the advantages of LBBP, including a high success rate, stable pacing parameters, and excellent clinical benefits. Widespread adoption of LBBP will depend on improvements in device/lead technology and further verification of its efficacy in large randomized clinical trials.

This article summarizes recent advancements in LBBP, including the definition and evaluation of left bundle branch capture, LBBP applications, and future directions in this growing field.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0047

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Jiaxing Zeng, Siyuan Xue and Fengwei Zou et al. Advances in Left Bundle Branch Pacing: Definition, Evaluation, and Applications. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0047

Loading

Phrenic Nerve Injury During Ablation of Atrial Fibrillation: Mechanisms, Clinical Features, Prognosis, and Prevention Methods

Announcing a new article publication for Cardiovascular Innovations and Applications journal.    Atrial fibrillation ablation procedures have become a focus of research among electrophysiologists, with the aim of increasing success rates while minimizing complications. One major concern is phrenic nerve injury (PNI). Despite advancements in ablation strategies, equipment, and monitoring methods, the incidence of PNI during these procedures remains substantial, particularly during cryoballoon ablation, which has a reported PNI incidence of 3.5%.

This article examines recent studies, to provide a comprehensive overview of PNI mechanisms, clinical features, prognosis, and methods for prevention during ablation.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0050

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Xinmeng Liu, Rong Lin and Xiaodong Peng et al. Phrenic Nerve Injury During Ablation of Atrial Fibrillation: Mechanisms, Clinical Features, Prognosis, and Prevention Methods. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0050

Loading

Transcatheter Aortic Valve Replacement for Aortic Regurgitation

Announcing a new article publication for Cardiovascular Innovations and Applications journal.  Transcatheter aortic valve replacement (TAVR) is currently a widely used option for patients with severe symptomatic aortic stenosis with high to low surgical risk. However, aortic regurgitation (AR) remains an “off-label” indication for TAVR, particularly for patients with mild or absent leaflet calcification or aortic annulus dimensions beyond the size of the bioprosthesis, which increase the risk of dislocation. With advances in transcatheter heart valve devices, the safety and efficacy of TAVR in treating patients with severe pure native AR has gained acceptance.

This article examines current evidence and clinical practice, and presents technological advancements in devices for AR.

Read full article at Scienceopen: https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0033

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Ran Liu, Zhaolin Fu and Jing Yao et al. Transcatheter Aortic Valve Replacement for Aortic Regurgitation – A Review. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0033

Loading

Post-Translational Modification of Drp1 is a Promising Target for Treating Cardiovascular Diseases

Announcing a new article publication for Cardiovascular Innovations and Applications journal.    Mitochondria are essential for cell growth, fission, differentiation, and survival, particularly in undivided cells with high energy requirements, such as cardiomyocytes. The morphology and position of mitochondria change with the activity of mitochondrial fission proteins and mitochondrial fusion proteins. These regulatory mechanisms substantially affect cardiomyocyte energy supply and normal function. In mitochondrial fission, dynamin-related protein 1 (Drp1) is involved in the separation and degradation of damaged mitochondria, and accurately regulates mitochondrial renewal and number. Recent studies have revealed a variety of post-translational modification (PTMs) of Drp1, including phosphorylation, SUMOylation, acetylation, O-GlcNAcylation, and S-sulfhydration. These modifications ensure that Drp1 continues to function normally in various signaling pathways, by modulating its activity, stability, and subcellular localization.

This article provides an overview of the relationship between Drp1 PTMs and cardiovascular diseases such as heart failure, myocardial infarction, and myocardial ischemia-reperfusion, and describes how these modifications can be targeted and regulated, to help guide cardiovascular disease treatment.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0043

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Yingjie Ji, Han Zhou and Chen Yang et al. Post-Translational Modification of Drp1 is a Promising Target for Treating Cardiovascular Diseases. CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0043

Loading

Sex Differences in Transcatheter Structural Heart Disease Interventions: How Much Do We Know?

Announcing a new article publication for Cardiovascular Innovations and Applications journal.  The number of structural heart disease interventions has greatly increased in the past decade. Moreover, interest in the sex-specific outcomes of various cardiovascular conditions and procedures has increased. The authors of this article discuss the sex differences in the clinical profiles and outcomes of patients undergoing the most commonly performed structural procedures: transcatheter aortic valve replacement, transcatheter edge to edge repair of the mitral and tricuspid valve, transcatheter pulmonary valve replacement, patent foramen ovale closure and left atrial appendage occlusion. The potential reasons for these differences are reviewed and the authors emphasize the importance of increasing the representation of women in randomized clinical trials, to understand these differences and support the application of these cutting-edge technologies.

https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2023.0049

CVIA is available on the ScienceOpen platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. Cardiovascular Innovations and Applications is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life and Ulrich’s web Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Lina Ya’Qoub, Jelena Arnautovic and Nadeen N. Faza et al. Sex Differences in Transcatheter Structural Heart Disease Interventions: How Much Do We Know? CVIA. 2023. Vol. 8(1). DOI: 10.15212/CVIA.2023.0049

Loading

Cardiovascular Innovations and Applications Achieves New Milestone

The Co-Editors-in-Chief of Cardiovascular Innovations and Applications (CVIA), Jamie B. Conti, University of Florida, Gainesville, FL, USA and Jianzeng Dong, Beijing Anzhen Hospital, Capital Medical University, Beijing, China are pleased to announce the inclusion of CVIA in the 2023 Journal Citation Reports (JCR) from Clarivate.

CVIA, received its first Journal Impact Factor (JIF) of 0.5 this year after being launched in 2016 and accepted into Emerging Sources Citation Index (ESCI) in 2018. 

About CVIA

Cardiovascular Innovations and Applications (CVIA) seeks to publish focused articles and original clinical research that explore novel developments in cardiovascular disease, effective control and rehabilitation in cardiovascular disease, and promote cardiovascular innovations and applications for the betterment of public health globally. The journal publishes basic research that has clinical applicability to promote timely communication of the latest insights relating to coronary artery disease, heart failure, hypertension, cardiac arrhythmia, prevention of cardiovascular disease with a heavy emphasis on risk factor modification.

CVIA  as an open access journal offers high visibility and discoverability through its open access publishing approach. As part of its mandate to help bring interesting work and knowledge from around the world to a wider audience, CVIA will actively support authors through open access publishing and through waiving of author fees.  

The journal welcomes the following article types:

  • Editorials
  • Original Research
  • Review Articles
  • Commentaries
  • Case Reports
  • Case Studies
  • Methodology papers related to clinical trials
  • Letters to the Editor

Benefits of choosing CVIA for your research

  • CVIA is a platinum open access journal which means that your paper is available to anyone in the world to download for free directly from the ScienceOpen website.
  • No Author submission or article processing charges.
  • Authors can retain the copyright to their article.
  • Fast peer review.
  • Fast publication online after article acceptance.
  • Unlike many traditional journals, your paper will not be rejected due to lack of space. We are an electronic journal and there are no limits on the number or size of the papers we can publish.
  • Professional/global marketing/promotion of your articles. Articles are:
  • Sent to clinicians and researchers in the cardiovascular community through email alerts;
  • Promoted to the Journal followers on Twitter and Facebook;
  • Distributed to news outlets through press releases.

For more information on our journal please see the CVIA website https://cvia-journal.org/; recently published content is available on ScienceOpen  https://www.scienceopen.com/search#collection/32b77252-732d-468f-a6f9-9637d4762967 .

Submissions to Cardiovascular Innovations and Applications (CVIA) can be made using ScholarOne, the online submission and peer review system. Registration and access are available at https://mc04.manuscriptcentral.com/cvia-journal. There are no author submission or article processing fees.

Articles of interest include:

Machine Learning Methods in Real-World Studies of Cardiovascular Disease

Experience in Application of a Three-Dimensional Pulsed Field Ablation System Integrating Mapping and Ablation

Association between Percentage of Neutrophils at Admission and in-Hospital Events in Patients ≥75 Years of Age with Acute Coronary Syndrome

Spontaneous Heparin-Induced Thrombocytopenia Presenting as Concomitant Bilateral Cerebrovascular Infarction and Acute Coronary Syndrome

Advances in Renal Denervation in the Treatment of Hypertension

Elevated Monocyte to High-density Lipoprotein Ratio Is a Risk Factor for New-onset Atrial Fibrillation after Off-pump Coronary Revascularization

The Neutrophil/Lymphocyte Ratio is Associated with Different Stages of Development of Coronary Artery Disease

Immune Infiltration in Atherosclerosis is Mediated by Cuproptosis-Associated Ferroptosis Genes

Novel SPECT Technologies and Approaches in Cardiac Imaging

Lowering of Blood Lipid Levels with a Combination of Pitavastatin and Ezetimibe in Patients with Coronary Heart Disease: A Meta-Analysis

CVIA is indexed in the EMBASE, EBSCO, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ, Index Copernicus, Research4Life, CNKI Scholar (Chinese National Knowledge Infrastructure) and Ulrich’s web Databases.

Follow CVIA

Twitter @CVIA_JournalFacebookhttps://www.facebook.com/cvia.journal/

Loading